At the close on Thursday, shares in San Rafael, California headquartered BioMarin Pharmaceutical Inc. saw a decline of 1.23%, ending the day at $86.87. The stock recorded a trading volume of 1.91 million shares, which was above its three months average volume of 1.57 million shares. The Company's shares are trading below their 200-day moving average by 0.67%. Moreover, shares of BioMarin Pharmaceutical, which develops and commercializes pharmaceuticals for serious diseases and medical conditions in the US, Europe, Latin America, and internationally, have a Relative Strength Index (RSI) of 32.47.
On October 13th, 2016, BioMarin Pharmaceutical announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK approved continued enrollment into the open-label Phase 1/2 study of BMN 270, an investigational gene therapy treatment for severe hemophilia A. BioMarin had previously announced that after enrolling the first 9 patients in the study, that dosing of patients had been suspended due to observed increases in alanine aminotransferase (ALT) levels that exceeded a pre-specified threshold set by the company. The agency also approved the company's proposed amendments to the study, which included eliminating the requirement for prophylactic corticosteroids and increasing potential additional enrollment from up to three additional patients to up to six additional patients. BMRN complete research report is just a click away and free at: http://stock-callers.com/registration/?symbol=BMRN
Shares in Boston, Massachusetts headquartered Keryx Biopharmaceuticals Inc. ended the day 1.01% higher at $5.01, with a total trading volume of 1.59 million shares. In the last month, the stock has gained 8.68%. The Company's shares are trading above their 50-day moving average by 6.60%. Furthermore, shares of Keryx Biopharmaceuticals, which focuses on providing therapies for patients with renal disease in the US, have an RSI of 48.65. The complimentary report on KERX can be downloaded at: http://stock-callers.com/registration/?symbol=KERX
On Thursday, shares in Los Angeles, California headquartered Puma Biotechnology Inc. finished 0.66% lower at $56.09, with a total trading volume of 590,999 shares. The stock has soared 70.07% over the previous three months. The Company's shares are trading above their 200-day moving average by 28.75%. Additionally, shares of Puma Biotechnology, which focuses on the development and commercialization of products for the treatment of various forms of cancer, have an RSI of 42.02.
On September 20th, 2016, Puma Biotechnology announced that the US Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for its lead product candidate PB272 (neratinib) for the extended adjuvant treatment of patients with early stage HER2-overexpressed/amplified breast cancer who have received prior adjuvant trastuzumab (Herceptin®)-based therapy.
On September 22nd, 2016, research firm Credit Suisse reiterated its 'Outperform' rating on the Company's stock with an increase of the target price from $54 a share to $111 a share. Sign up for your complimentary research report on PBYI at: http://stock-callers.com/registration/?symbol=PBYI
Pasadena, California headquartered Arrowhead Pharmaceuticals Inc.'s shares recorded a trading volume of 669,828 shares at the end of yesterday's session and closed the day at $6.95, gaining 1.91%. The stock has advanced 19.62% in the previous three months and 13.01% on an YTD basis. The Company's shares are trading above their 50-day and 200-day moving averages by 0.36% and 24.92%, respectively. Additionally, shares of Arrowhead Pharmaceuticals, which develops novel drugs to treat intractable diseases in the US, have an RSI at 48.68.
On October 6th, 2016, Arrowhead Pharma and Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, cancer, and inflammatory diseases, announced an agreement to perform collaborative studies on Arrowhead's ARC-520 and Spring Bank's SB 9200, for the treatment of chronic Hepatitis B (HBV). The companies plan to first conduct preclinical models with both agents together and then study the agents clinically in a cohort to be added to Arrowhead's ongoing MONARCH Phase 2b study, in which patients will receive a dosing regimen that includes ARC-520, SB 9200, and an oral direct-acting antiviral. Get free access to your research report on ARWR at: http://stock-callers.com/registration/?symbol=ARWR
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://stock-callers.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA